Current status of sublingual immunotherapy for allergic rhinitis in Japan

Current status of sublingual immunotherapy for allergic rhinitis in Japan

Japanese cedar pollen (JCP) and house dust mite (HDM) are two major allergens that cause allergic rhinitis (AR) in Japan and the prevalence of AR is increasing. Pharmacothearpy is a commonly used treatment, but the level of patient satisfaction is very low. Allergen immunotherapy (AIT) is the only t...

Full description

Bibliographic Details
Main Authors: Keisuke Masuyama, Tomokazu Matsuoka, Atsushi Kamijo
Format: Article
Language:English
Published: Elsevier 2018-07-01
Series:Allergology International
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893018300546
id doaj-2eb1667f7f3441578cb8ad195376ba54
record_format Article
spelling doaj-2eb1667f7f3441578cb8ad195376ba542020-11-24T23:05:55ZengElsevierAllergology International1323-89302018-07-01673320325Current status of sublingual immunotherapy for allergic rhinitis in JapanKeisuke Masuyama0Tomokazu Matsuoka1Atsushi Kamijo2Corresponding author. Department of Otorhinolaryngology, Head and Neck Surgery, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan.; Department of Otorhinolaryngology, Head and Neck Surgery, University of Yamanashi, Yamanashi, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Yamanashi, Yamanashi, JapanDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Yamanashi, Yamanashi, JapanJapanese cedar pollen (JCP) and house dust mite (HDM) are two major allergens that cause allergic rhinitis (AR) in Japan and the prevalence of AR is increasing. Pharmacothearpy is a commonly used treatment, but the level of patient satisfaction is very low. Allergen immunotherapy (AIT) is the only therapeutic modality that provides not only symptom relief but also quality of life improvement that leads to a high rate of satisfaction. In particular, sublingual immunotherapy (SLIT) is a safe and effective treatment for AR. Here we introduce a large-scale double-blind, placebo-controlled trial of SLIT in Japanese patients using JCP droplets or HDM tablets conducted in Japan. The immediate future of SLIT in Japan is also discussed. Keywords: Allergen immunothearpy, Allergic rhinitis, HDM allergen, Japanese cedar pollinosis, Sublingual immunotherapyhttp://www.sciencedirect.com/science/article/pii/S1323893018300546
collection DOAJ
language English
format Article
sources DOAJ
author Keisuke Masuyama
Tomokazu Matsuoka
Atsushi Kamijo
spellingShingle Keisuke Masuyama
Tomokazu Matsuoka
Atsushi Kamijo
Current status of sublingual immunotherapy for allergic rhinitis in Japan
Allergology International
author_facet Keisuke Masuyama
Tomokazu Matsuoka
Atsushi Kamijo
author_sort Keisuke Masuyama
title Current status of sublingual immunotherapy for allergic rhinitis in Japan
title_short Current status of sublingual immunotherapy for allergic rhinitis in Japan
title_full Current status of sublingual immunotherapy for allergic rhinitis in Japan
title_fullStr Current status of sublingual immunotherapy for allergic rhinitis in Japan
title_full_unstemmed Current status of sublingual immunotherapy for allergic rhinitis in Japan
title_sort current status of sublingual immunotherapy for allergic rhinitis in japan
publisher Elsevier
series Allergology International
issn 1323-8930
publishDate 2018-07-01
description Japanese cedar pollen (JCP) and house dust mite (HDM) are two major allergens that cause allergic rhinitis (AR) in Japan and the prevalence of AR is increasing. Pharmacothearpy is a commonly used treatment, but the level of patient satisfaction is very low. Allergen immunotherapy (AIT) is the only therapeutic modality that provides not only symptom relief but also quality of life improvement that leads to a high rate of satisfaction. In particular, sublingual immunotherapy (SLIT) is a safe and effective treatment for AR. Here we introduce a large-scale double-blind, placebo-controlled trial of SLIT in Japanese patients using JCP droplets or HDM tablets conducted in Japan. The immediate future of SLIT in Japan is also discussed. Keywords: Allergen immunothearpy, Allergic rhinitis, HDM allergen, Japanese cedar pollinosis, Sublingual immunotherapy
url http://www.sciencedirect.com/science/article/pii/S1323893018300546
work_keys_str_mv AT keisukemasuyama currentstatusofsublingualimmunotherapyforallergicrhinitisinjapan
AT tomokazumatsuoka currentstatusofsublingualimmunotherapyforallergicrhinitisinjapan
AT atsushikamijo currentstatusofsublingualimmunotherapyforallergicrhinitisinjapan
_version_ 1725624980412039168

Similar Items